Provided by Tiger Trade Technology Pte. Ltd.

Urogen Pharma Ltd.

24.38
-4.0800-14.34%
Post-market: 24.400.0200+0.08%17:35 EST
Volume:1.39M
Turnover:35.94M
Market Cap:1.14B
PE:-7.04
High:28.69
Open:28.45
Low:24.00
Close:28.46
52wk High:30.00
52wk Low:3.42
Shares:46.81M
Float Shares:37.03M
Volume Ratio:1.57
T/O Rate:3.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4606
EPS(LYR):-2.9590
ROE:-1481.26%
ROA:-33.96%
PB:-9.89
PE(LYR):-8.24

Loading ...

UroGen Pharma Chief Medical Officer Mark Schoenberg Sells Common Shares

Reuters
·
Nov 21

UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN)

Simply Wall St.
·
Nov 16

Ladenburg Thalmann & Co. Sticks to Its Buy Rating for Urogen Pharma (URGN)

TIPRANKS
·
Nov 08

Stock Track | UroGen Pharma Plummets 5.06% in Pre-market: Potential Profit-Taking After Recent Surge

Stock Track
·
Nov 07

Stock Track | Urogen Pharma Plummets 5.06% in Pre-market Despite Recent Positive Developments

Stock Track
·
Nov 07

Stock Track | UroGen Pharma Plunges 8.16% as Q3 Revenue Misses Estimates Despite Promising Pipeline

Stock Track
·
Nov 07

Stock Track | Urogen Pharma Plunges 8% Following Q3 Earnings Miss and Mixed Outlook

Stock Track
·
Nov 07

UroGen Q3 2025 Earnings Call Summary and Q&A Highlights: Zasturi Launch and Pipeline Progress

Earnings Call
·
Nov 07

UroGen (URGN) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Nov 07

UroGen Says FDA Agrees to New Drug Application for UGN-103 Based on Phase 3 Data

MT Newswires Live
·
Nov 06

Stock Track | Urogen Pharma Plunges 9.37% Pre-market on Q3 Revenue Miss and Declining Cash Position

Stock Track
·
Nov 06

Stock Track | Urogen Pharma Plunges 9.37% Pre-market Following Q3 Revenue Miss

Stock Track
·
Nov 06

Earnings Flash (URGN) UroGen Pharma Posts Q3 Net Loss $0.69 a Share, vs. FactSet Est of $0.69 Loss

MT Newswires Live
·
Nov 06

UroGen Pharma reports Q3 revenue of $27.5 million

Reuters
·
Nov 06

UroGen Pharma Reports 77.8% Complete Response Rate in Phase 3 UTOPIA Trial for UGN-103

Reuters
·
Nov 06

Urogen Pharma Ltd expected to post a loss of 69 cents a share - Earnings Preview

Reuters
·
Nov 04

UroGen Pharma Ltd. to Release Third Quarter 2025 Results

Reuters
·
Oct 30

Analysts’ Top Healthcare Picks: Urogen Pharma (URGN), AngioDynamics (ANGO)

TIPRANKS
·
Oct 27

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Oct 27

UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues

Simply Wall St.
·
Oct 06